Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Beta Carotene

FDA-approved product (capsule, oral), marketed as Solatene.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Beta Carotene
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Beta Carotene. Its therapeutic class is shown instead.

WHO therapeutic group
Vitamin a, plain; Protectives against uv-radiation for systemic use
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Beta Carotene, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA18.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli22.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae10.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis35.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Beta Carotene in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Beta Carotene with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • 9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients

    NCT07509229 · start 2026-07-26

    Registered record
    Registry ID
    NCT07509229
    Conditions
    Retinitis Pigmentosa
    Interventions
    9-cis beta-Carotene-rich extract of Dunaliella alga; Placebo Corn Oil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Enrolling by invitation
    Start
    2026-07-26
    Completion
    2029-04-30
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRetinitis Pigmentosa
    Intervention9-cis beta-Carotene-rich extract of Dunaliella alga; Placebo Corn Oil
    PhasePhase 1 / Phase 2
    Registry statusEnrolling by invitation

  • Algal Lutein Against Decline of Intellectual Nimbleness

    NCT07600567 · start 2026-05-01

    Registered record
    Registry ID
    NCT07600567
    Conditions
    Menopausal Syndrome; Cognitive Decline; Obesity & Overweight; Menopause; Inflamation; Gut Dysbiosis; Bisphenol A; Cardio Vascular Disease
    Interventions
    Lutein; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-05-01
    Completion
    2027-04-30
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenopausal Syndrome; Cognitive Decline; Obesity & Overweight; Menopause +4 more
    InterventionLutein; Placebo
    PhaseNot applicable
    Registry statusNot yet recruiting

  • The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa

    NCT02018692 · start 2026-03-01

    Registered record
    Registry ID
    NCT02018692
    Conditions
    Retinitis Pigmentosa
    Interventions
    Alga Dunaliella Bardawil powder; Placebo:Starch
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-03-01
    Completion
    2028-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRetinitis Pigmentosa
    InterventionAlga Dunaliella Bardawil powder; Placebo:Starch
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Early Identification and Treatment of Rare Cardiomyopathy Cohorts

    NCT06794710 · start 2025-02-01

    Registered record
    Registry ID
    NCT06794710
    Conditions
    Hypertrophic Cardiomyopathy (HCM); Dilated Cardiomyopathy (DCM); Metabolic Cardiomyopathy; Restrictive Cardiomyopathy
    Interventions
    diuretics, ACEIs/ARBs, beta blockers, positive inotropic drugs, MRAs, SGLT2i, retinoids; Close follow-up; early rehabilitation guidance
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-02-01
    Completion
    2027-09-30
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertrophic Cardiomyopathy (HCM); Dilated Cardiomyopathy (DCM); Metabolic Cardiomyopathy; Restrictive Cardiomyopathy
    Interventiondiuretics, ACEIs/ARBs, beta blockers, positive inotropic drugs, MRAs, SGLT2i, retinoids; Close follow-up; early rehabilitation guidance
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Wide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy

    NCT06137833 · start 2023-11-27

    Registered record
    Registry ID
    NCT06137833
    Conditions
    Fatigue; Breast Cancer
    Interventions
    APPOPRTAL®; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-11-27
    Completion
    2025-12-31
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFatigue; Breast Cancer
    InterventionAPPOPRTAL®; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Effect of Eurycoma Longifolia (DLBS5055) and Multivitamins (Vitamin C+Vitamin E+ β-carotene) for Infertile Males

    NCT06100432 · start 2023-11-11

    Registered record
    Registry ID
    NCT06100432
    Conditions
    Male Infertility
    Interventions
    DLBS5055 200mg; Placebo DLBS5055; Multivitamin (Vitamin C 500mg + Vitamin E 100IU + Beta Carotene 10000IU); Placebo Multivitamin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2023-11-11
    Completion
    2025-10-31
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMale Infertility
    InterventionDLBS5055 200mg; Placebo DLBS5055; Multivitamin (Vitamin C 500mg + Vitamin E 100IU + Beta Carotene 10000IU); Placebo Multivitamin
    PhasePhase 4
    Registry statusActive not recruiting

  • Age Related Effects Consuming Phaeodactylum Tricornutum

    NCT05120791 · start 2022-07

    Registered record
    Registry ID
    NCT05120791
    Conditions
    Aging; Well Aging
    Interventions
    Placebo vegetable bouillon; microalgae phaeodactylum; From the Microalgae phaeodactylum the extracted beta-Glucan (especially chrysolaminarin); A combination of the vegetable bouillon, the microalgae and the beta-Glucan
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-07
    Completion
    2022-08
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAging; Well Aging
    InterventionPlacebo vegetable bouillon; microalgae phaeodactylum; From the Microalgae phaeodactylum the extracted beta-Glucan (especially chrysolaminarin); A combination of the vegetable bouillon, the microalgae and the beta-Glucan
    PhaseNot applicable
    Registry statusUnknown

  • Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma

    NCT05373901 · start 2022-06-07

    Registered record
    Registry ID
    NCT05373901
    Conditions
    High-risk Neuroblastoma
    Interventions
    Dinutuximab Beta; 13-cis-Retinoic Acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-06-07
    Completion
    2023-06-29
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh-risk Neuroblastoma
    InterventionDinutuximab Beta; 13-cis-Retinoic Acid
    PhasePhase 1
    Registry statusCompleted

  • Beta-cryptoxanthin Supplement: Absorption and Function

    NCT05046457 · start 2021-09-07

    Registered record
    Registry ID
    NCT05046457
    Conditions
    Beta-cryptoxanthin Supplementation
    Interventions
    Beta-cryptoxanthin (BCX)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-09-07
    Completion
    2022-03-31
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBeta-cryptoxanthin Supplementation
    InterventionBeta-cryptoxanthin (BCX)
    PhaseNot applicable
    Registry statusCompleted

  • Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19

    NCT04551339 · start 2020-09-28

    Registered record
    Registry ID
    NCT04551339
    Conditions
    Healthy; Health Care Worker Patient Transmission; Aging
    Interventions
    PreserVision AREDS formulation soft gels or tablets; Multivitamin with 11mg of zinc
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-09-28
    Completion
    2021-05-28
    Enrolment
    2,700

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy; Health Care Worker Patient Transmission; Aging
    InterventionPreserVision AREDS formulation soft gels or tablets; Multivitamin with 11mg of zinc
    PhaseNot applicable
    Registry statusCompleted

  • Evaluation of the Efficacy of a Food Supplement in Reducing Hair Loss in Male Subjects

    NCT04884347 · start 2020-08-31

    Registered record
    Registry ID
    NCT04884347
    Conditions
    Hair Loss
    Interventions
    Alline proMEN; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-08-31
    Completion
    2021-02-04
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHair Loss
    InterventionAlline proMEN; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • The Role of Vitamin D, A, and Beta Carotene in Tuberculosis Patients With Vitamin D Receptor Gene Polymorphism

    NCT04593524 · start 2019-05-14

    Registered record
    Registry ID
    NCT04593524
    Conditions
    Tuberculosis
    Interventions
    vitamin D 1000 IU and A 6000 IU supplementation and nutritional counseling; nutritional Counseling
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-05-14
    Completion
    2019-09-22
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Interventionvitamin D 1000 IU and A 6000 IU supplementation and nutritional counseling; nutritional Counseling
    PhaseNot applicable
    Registry statusCompleted

  • Bioefficacy of Beta-cryptoxanthin From Biofortified Maize

    NCT04153968 · start 2019-04-01

    Registered record
    Registry ID
    NCT04153968
    Conditions
    Vitamin A Deficiency
    Interventions
    β-cryptoxanthin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-04-01
    Completion
    2020-12-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVitamin A Deficiency
    Interventionβ-cryptoxanthin
    PhaseNot applicable
    Registry statusUnknown

  • Lycopene vs Minocycline Hydrochloride as Adjunctive to Periodontal Treatment

    NCT03964935 · start 2018-12-01

    Registered record
    Registry ID
    NCT03964935
    Conditions
    Periodontal Pocket
    Interventions
    Lycopene; Minocycline HCl 1mg Oral Powder; Distilled water
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-12-01
    Completion
    2019-08-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeriodontal Pocket
    InterventionLycopene; Minocycline HCl 1mg Oral Powder; Distilled water
    PhasePhase 2
    Registry statusUnknown

  • Influence of Inflammation on Micronutrient Status Assessment

    NCT03801161 · start 2018-06-01

    Registered record
    Registry ID
    NCT03801161
    Conditions
    Healthy Infants
    Interventions
    Pentavalent vaccine. It is a combination of five different antigens (Hepatitis B (HBV)/ Haemophilus influenzae type b (HiB) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-06-01
    Completion
    2019-06-30
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Infants
    InterventionPentavalent vaccine. It is a combination of five different antigens (Hepatitis B (HBV)/ Haemophilus influenzae type b (HiB) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).
    PhaseNot applicable
    Registry statusCompleted